Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene–Driven Non–Small Cell Lung Cancer (TURBO-NSCLC)

Author(s): Luke R.G. Pike, MD, DPhil¹; Emily Miao, PharmD^1,2; Lillian A. Boe, PhD³; Tejas Patil, MD⁴; Brandon S. Imber, MD¹; Nathaniel J. Myall, MD⁵; Erqi L. Pollom, MD, MS⁶; Caressa Hui⁶; Vera Qu, MD⁶; Jacob Langston, MD⁷; Veronica Chiang, MD⁸; Michael Grant, MD⁹; Sarah B. Goldberg, MD, MPH⁹; Joshua D. Palmer, MD¹⁰; Rahul N. Prasad, MD, MBA¹⁰; Tony J.C. Wang, MD¹¹; Albert Lee, MD¹¹; Catherine A. Shu, MD¹²; Lanyi Nora Chen, MD¹²; Nicholas J. Thomas, MD¹³; Steve E. Braunstein, MD, PhD¹⁴; Brian D. Kavanagh, MD⁷; D. Ross Camidge, MD, PhD⁴; Chad G. Rusthoven, MDedu⁷

Source: https://doi.org/10.1200/JCO.23.02668

Dr. Maen Hussein's Thoughts

Adding SBRT improves local control and disease progression in the brain but not overall survival. Do the radiation oncologists have input? Is it worth it to control symptoms?

PURPOSE

Newer-generation tyrosine kinase inhibitors (TKIs) for non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements have demonstrated high CNS activity. The optimal use of up-front stereotactic radiosurgery (SRS) for brain metastases (BM) in patients eligible for CNS-penetrant TKIs is controversial, and data to guide patient management are limited.

MATERIALS AND METHODS

Data on TKI-naïve patients with EGFR- and ALK-driven NSCLC with BM treated with CNS-penetrant TKIs with and without up-front SRS were retrospectively collected from seven academic centers in the United States. Time-to-CNS progression and overall survival (OS) were analyzed, with multivariable adjustment in Fine & Gray and Cox proportional hazards models for clinically relevant factors.

RESULTS

From 2013 to 2022, 317 patients were identified (200 TKI-only and 117 TKI + SRS). Two hundred fifty (79%) and 61 (19%) patients received osimertinib and alectinib, respectively. Patients receiving TKI + SRS were more likely to have BM ≥1 cm (P < .001) and neurologic symptoms (P < .001) at presentation. Median OS was similar between the TKI and TKI + SRS groups (median 41 v 40 months, respectively; P = .5). On multivariable analysis, TKI + SRS was associated with a significant improvement in time-to-CNS progression (hazard ratio [HR], 0.63 [95% CI, 0.42 to 0.96]; P = .033). Local CNS control was significantly improved with TKI + SRS (HR, 0.30 [95% CI, 0.16 to 0.55]; P < .001), whereas no significant differences were observed in distant CNS control. Subgroup analyses demonstrated a greater benefit from TKI + SRS in patients with BM ≥1 cm in diameter for time-to-CNS progression and CNS progression-free survival.

CONCLUSION

The addition of up-front SRS to CNS-penetrant TKI improved time-to-CNS progression and local CNS control, but not OS, in patients with BM from EGFR- and ALK-driven NSCLC. Patients with larger BM (≥1 cm) may benefit the most from up-front SRS.

Author Affiliations

¹Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY; ²Albert Einstein College of Medicine, Bronx, NY; ³Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY; ⁴Division of Hematology and Oncology, Department of Medicine, University of Colorado, Aurora, CO; ⁵Division of Hematology and Oncology, Department of Medicine, Stanford University, Palo Alto, CA; ⁶Department of Radiation Oncology, Stanford University, Palo Alto, CA; ⁷Department of Radiation Oncology, University of Colorado, Aurora, CO; ⁸Department of Neurosurgery, Yale University, New Haven, CT; ⁹Division of Medical Oncology, Department of Medicine, Yale School of Medicine, New Haven, CT; ¹⁰Department of Radiation Oncology, Ohio State University, Columbus, OH; ¹¹Department of Radiation Oncology, Columbia University Irving Medical Center, New York, NY; ¹²Division of Hematology and Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY; ¹³Department of Medicine, University of California San Francisco, San Francisco, CA; ¹⁴Department of Radiation Oncology, University of California San Francisco, San Francisco, CA

Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2

The CHRYSALIS-2, the cohort C analysis of patients with atypical EGFR mutations showed meaningful and durable activity. Atypical mutations can be difficult to deal with as a clinician, and having concrete data on these (S768I, L861Q and G719ZX) mutations gives assurance that this doublet is active. Overall response rate (ORR) was 52% and median progression-free survival (PFS) was 11.1 months in refractory patients and 19.5 months in the treatment-naive population.

Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC

The final overall survival (OS) analysis from the FLAURA2 confirms the well-published findings that Osi + chemo improves survival over Osi monotherapy. OS difference was about 10 months at 47 vs 37 months, with a predictable toxicity tradeoff.

Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non–Small Cell Lung Cancer

This update demonstrated that encorafenib plus binimetinib was associated with the longest median overall survival (mOS) reported to date among targeted therapies in patients with treatment-naïve BRAF V600E–mutant metastatic NSCLC (mNSCLC). Median OS was 47.6 months in treatment-naïve patients. By the way check the authors there 😊.

Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: The Phase III PACIFIC-2 Study

PACIFIC-2 was a phase III trial testing durva given concurrently with cCRT (and continued as consolidation) versus placebo + cCRT in unresectable stage III NSCLC, and it did not meet its primary endpoint. The overall response rate (ORR) was essentially identical (60.7% vs 60.6%), and pneumonitis rates were similar (any grade 28.8% vs 28.7%; grade ≥3: 4.6% vs 5.6%), but adverse events (AEs) leading to discontinuation and fatal AEs were higher with durva (25.6% vs 12.0%; 13.7% vs 10.2%), especially early on. Starting IO up front with cCRT didn’t improve outcomes and added early toxicity—consolidation durva after cCRT is still the way to go.

Sevabertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer

Sevabertinib shows strong efficacy in HER2-mutant NSCLC, with an overall response rate (ORR) of 64% and median progression-free survival (PFS) of 8.3 months in previously treated, HER2-TKI–naive patients, and an overall response rate (ORR) of 71% with a duration of response (DOR) of 11.0 months in first-line therapy. Activity is highest in TKD mutations, especially Y772_A775dupYVMA, and intracranial responses are seen. Safety is manageable: diarrhea is common but mostly low grade, with grade ≥3 in 5–23% and rare discontinuations. Notably, interstitial lung disease (ILD) was not observed. These data position sevabertinib as a viable oral TKI alongside ADCs for HER2-mutant NSCLC, particularly for TKD/YVMA disease.